Passport Capital Has Trimmed Its Vulcan Matls Co (VMC) Stake; Profile of 3 Analysts Covering Novavax, Inc. (NVAX)

December 7, 2017 - By Michael Collier

Passport Capital Llc decreased Vulcan Matls Co (VMC) stake by 6.54% reported in 2017Q2 SEC filing. Passport Capital Llc sold 3,701 shares as Vulcan Matls Co (VMC)’s stock rose 5.55%. The Passport Capital

Llc holds 52,859 shares with $6.70M value, down from 56,560 last quarter. Vulcan Matls Co now has $16.08 billion valuation. The stock increased 0.39% or $0.47 during the last trading session, reaching $121.58. About 13,562 shares traded. Vulcan Materials Company (NYSE:VMC) has risen 10.59% since December 7, 2016 and is uptrending. It has underperformed by 6.11% the S&P500.

Among 10 analysts covering Novavax (NASDAQ:NVAX), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Novavax had 21 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Hold” rating by Cantor Fitzgerald on Thursday, August 10. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Neutral” rating by Piperjaffray on Friday, September 16. Chardan Capital Markets initiated the shares of NVAX in report on Monday, April 4 with “Neutral” rating. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Buy” rating by Ladenburg Thalmann on Wednesday, August 9. The company was maintained on Tuesday, August 11 by Piper Jaffray. Citigroup downgraded the shares of NVAX in report on Friday, September 16 to “Neutral” rating. The rating was maintained by Cantor Fitzgerald with “Hold” on Tuesday, November 14. The rating was maintained by Chardan Capital Markets with “Neutral” on Tuesday, September 20. JP Morgan downgraded Novavax, Inc. (NASDAQ:NVAX) on Friday, September 16 to “Neutral” rating. Piper Jaffray maintained it with “Hold” rating and $1.5000 target in Monday, July 24 report. See Novavax, Inc. (NASDAQ:NVAX) latest ratings:

14/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0 Maintain
08/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0 Maintain
31/10/2017 Broker: Citigroup Old Rating: Neutral New Rating: Buy Upgrade
06/10/2017 Broker: Seaport Global Rating: Neutral Initiates Coverage On
19/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $1.5 Maintain
10/08/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0000 Maintain
09/08/2017 Broker: Ladenburg Thalmann Old Rating: Neutral New Rating: Buy Upgrade
24/07/2017 Broker: Piper Jaffray Rating: Hold New Target: $1.5000 Maintain
21/07/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0000 Maintain

Among 13 analysts covering Vulcan Materials Company (NYSE:VMC), 9 have Buy rating, 0 Sell and 4 Hold. Therefore 69% are positive. Vulcan Materials Company had 32 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Vulcan Materials Company (NYSE:VMC) has “Buy” rating given on Friday, August 14 by Argus Research. The firm has “Buy” rating given on Wednesday, October 26 by Suntrust Robinson. The stock has “Buy” rating by RBC Capital Markets on Monday, July 24. The firm earned “Buy” rating on Monday, October 9 by RBC Capital Markets. The firm earned “Outperform” rating on Wednesday, August 5 by RBC Capital Markets. The firm has “Buy” rating given on Wednesday, October 26 by SunTrust. The firm has “Buy” rating by Citigroup given on Monday, October 9. The stock has “Outperform” rating by RBC Capital Markets on Friday, February 5. The company was initiated on Wednesday, March 29 by Citigroup. The company was maintained on Tuesday, September 26 by Stifel Nicolaus.

Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.22, from 1.17 in 2017Q1. It is negative, as 44 investors sold VMC shares while 183 reduced holdings. 63 funds opened positions while 153 raised stakes. 112.23 million shares or 1.83% more from 110.22 million shares in 2017Q1 were reported. Covington has 16,096 shares for 0.16% of their portfolio. Oakworth Capital invested in 1,762 shares or 0.06% of the stock. Bamco Ny reported 264,886 shares or 0.17% of all its holdings. Aqr Capital Mgmt Llc invested in 14,211 shares or 0% of the stock. Howard Cap Management holds 1.43% of its portfolio in Vulcan Materials Company (NYSE:VMC) for 71,897 shares. Massmutual Trust Com Fsb Adv reported 1,883 shares. Blair William Il has invested 0.03% in Vulcan Materials Company (NYSE:VMC). The Minnesota-based Advantus Mgmt has invested 0.04% in Vulcan Materials Company (NYSE:VMC). Ig Inv Management Limited has invested 0.01% of its portfolio in Vulcan Materials Company (NYSE:VMC). Commerzbank Aktiengesellschaft Fi has invested 0% of its portfolio in Vulcan Materials Company (NYSE:VMC). Passport Cap Llc owns 0.89% invested in Vulcan Materials Company (NYSE:VMC) for 52,859 shares. New York-based Sandler Capital has invested 0.8% in Vulcan Materials Company (NYSE:VMC). Lombard Odier Asset Mgmt (Europe) reported 0.01% of its portfolio in Vulcan Materials Company (NYSE:VMC). Smithfield Trust has 0.01% invested in Vulcan Materials Company (NYSE:VMC) for 461 shares. Thompson Siegel And Walmsley Limited Company has 0% invested in Vulcan Materials Company (NYSE:VMC) for 860 shares.

Analysts await Vulcan Materials Company (NYSE:VMC) to report earnings on February, 6. They expect $0.78 earnings per share, up 13.04% or $0.09 from last year’s $0.69 per share. VMC’s profit will be $103.18 million for 38.97 P/E if the $0.78 EPS becomes a reality. After $1.04 actual earnings per share reported by Vulcan Materials Company for the previous quarter, Wall Street now forecasts -25.00% negative EPS growth.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $437.36 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>